1. Introduction {#sec1}
===============

The buff-tailed bumblebee, *Bombus terrestris* (Hymenoptera: Apidae) is one of the most abundant bumblebee species in Europe and an important pollinator of wild plants and crops. Domesticated colonies are used for managed pollination of crops in orchards and greenhouses and are one of the main commercial alternatives to the western honey bee, *Apis mellifera* ([@bib4]; [@bib19]). Apart from their commercial importance bumblebees are also used as a model species for bee population genetics and the study of insect behaviour ([@bib20]).

The effect of xenobiotics on the health of bee pollinators has been the focus of considerable recent research, particularly in relation to the extensive use of synthetic insecticides in agriculture ([@bib5]). The effect of insecticidal exposure on the overall fitness of individuals and colonies of this species is still a topic of active investigation ([@bib15]; [@bib21]). However, concerns over the effects of three *N*-nitroguanidine neonicotinoid insecticides, imidacloprid, thiamethoxam and clothianidin on bee pollinators, including *B. terrestris,* has led the European Union to ban these compounds for use on field crops ([@bib3]). Due to their high acute intrinsic toxicity to *B. terrestris* these three compounds are all classified as 'highly toxic' according to the categories delineated by the U.S. Environmental Protection Agency ([@bib10]). In contrast *B. terrestris* exhibits a marked tolerance to *N*-cyanoamidine neonicotinoids, with thiacloprid classified as 'practically non-toxic' in acute contact bioassays ([@bib18]; [@bib10]). Similar differences have been described for the toxicity of the *N*-nitroguanidines and *N*-cyanoamidines to the western honey bee, *A. mellifera* ([@bib10]), and the solitary red mason bee, *Osmia bicornis* ([@bib2]).

Recent research has provided a biochemical explanation for this observed differential sensitivity and shown that, in all three bee species, P450 enzymes from the CYP9 family efficiently detoxify *N*-cyanoamidine compounds but have little activity against *N*-nitroguanidine compounds, thus acting as molecular determinants of bee sensitivity to neonicotinoids ([@bib2]; [@bib10]). In *B. terrestris* two P450s, CYP9Q4 and CYP9Q5, were previously shown to efficiently metabolise the *N*-cyanoamidine neonicotinoids thiacloprid and acetamiprid; however their overall combined activity in enzyme assays was significantly lower than that of CYP9Q3, the primary P450 metabolising these neonicotinoids in *A. mellifera*, leading us to speculate that additional P450s may play a role in neonicotinoid metabolism in bumblebees ([@bib10]). Here we report the identification and functional characterisation of a novel CYP9Q from *B. terrestris*, CYP9Q6, and demonstrate it to be an efficient detoxifier of *N*-cyanoamidine neonicotinoids.

2. Methods {#sec2}
==========

2.1. Insects and chemicals {#sec2.1}
--------------------------

Worker bees used for the experiments came from *Bombus terrestris* commercial colonies (standard hives) supplied by Biobest (Belgium). Colonies were kept in the dark at 27±1 °C, 50% relative humidity. All chemicals were supplied by Sigma-Aldrich unless stated otherwise.

2.2. Preparation of nucleic acids {#sec2.2}
---------------------------------

DNA and RNA extractions were done on single adult worker bees. DNA was extracted using the E.Z.N.A. Insect DNA kit (Omega-BioTek, USA) following the manufacture\'s protocol. Total RNA was extracted using Triazol reagent (ThermoScientific, USA) following the manufacturer\'s protocol. 4  μg of RNA was used for cDNA synthesis using SuperScript^®^ III reverse transcriptase (Life Technologies, USA) with Oligo~d~T~(15)~ primer (Promega, USA).

2.3. RT-PCR, sub-cloning and sequencing {#sec2.3}
---------------------------------------

PCR was performed using *pfu* polymerase (Promega, USA) in 25 μl reactions containing; 1  μl of cDNA or genomic DNA template, 10 pmol of each forward and reverse primer (see [Supplementary Table 1](#appsec1){ref-type="sec"} for primer details), and 1.5U of enzyme. Cycling conditions comprised an initial denaturation at 95 °C for 3 min, followed by 35 cycles of 95 °C for 20s, 55 °C for 30s, 72 °C for 4 min, with a final extension step at 72 °C for 5 min. PCR amplicons were separated using 1% w/v TAE gel electrophoresis, and products of the expected size were excised from the gel and recovered using Qiaquick gel extraction kit (Qiagen, Germany), following the manufacturer\'s protocol. PCR products were sequenced directly using Eurofins value read service (Germany). Bands which represented full-length ORF were further ligated into the pJET 1.2 vector of GeneJET PCR cloning kit (ThermoScientific, USA), and transformed into XL-1 blue cells (Agilent, USA). Plasmid preps were prepared using a GeneJET mini-prep kit (ThermoScientific, USA), following the manufacturer\'s protocol.

2.4. Tissue-specific qPCR {#sec2.4}
-------------------------

Bumblebees were dissected in PBS (phosphate buffered saline) buffer, and total RNA was prepared from tissues of a single female worker as described above. Two μg of RNA was used for cDNA synthesis as described above. PCR reactions (15 μl) contained 4 μl of cDNA (diluted 1:10 v/v), 7.5 μl of SYBR^®^ Green JumpStart™ Taq ReadyMix (Sigma-Aldrich, USA), and 0.25 μM of each primer ([Supplementary Table 1](#appsec1){ref-type="sec"}). Cycling conditions comprised 3 min at 95 °C, followed by 39 cycles of 95 °C for 15s, 64 °C for 15s and 60 °C for 15s. A final melt-curve step was included post-PCR (ramping from 65 to 95 °C by 0.5 °C every 5s) to confirm the absence of any non-specific amplification. The efficiency of PCR for each primer pair was assessed using a serial dilution of 100 ng--0.01 ng of cDNA. Each qPCR experiment consisted of at least 8 independent biological replicates with three technical replicates for each. Data were analysed according to the 2^−ΔΔCt^ method ([@bib14]) in MS excel 365 (Microsoft). The expression level was normalized to two validated reference genes, PLA2 (phospholipase A2) and EEF1A ([Supplementary Table 1](#appsec1){ref-type="sec"}) ([@bib6]). Data was visualised using GraphPad prism v7 (GraphPad Software, USA).

2.5. Baculovirus-mediated protein expression {#sec2.5}
--------------------------------------------

*B. terrestris* CYP9Q6 and house fly NADPH-dependent cytochrome P450 reductase (CPR) (GenBank accession no. [Q07994](ncbi-p:Q07994){#intref0010}) were codon optimised for expression in lepidopteran cell lines, synthesised by GeneArt^®^ (Life Technologies, USA), and inserted into the pDonor221 expression vector (Invitrogen). The recombinant baculovirus DNA was synthesised *in vitro* and transfected into *Trichoplusia ni* High five™ cells using the BaculoDirect C-term expression kit (Life Technologies, USA), according to the manufacturer\'s protocol. The titre of the recombinant virus was determined following protocols detailed by the supplier. High Five™ cells (Life Technologies, USA), grown to a density of 2 × 10^6^ cells ml^−1,^ were co-infected with recombinant baculoviruses containing CYP9Q6 and CPR with a range of MOI (multiplicity of infection) ratios to identify the optimal conditions. Control cells were co-infected with the baculovirus containing vector with no insert (ctrl-virus) and the recombinant baculovirus expressing CPR using the same MOI ratios. Ferric citrate and δ-aminolevulinic acid hydrochloride were added to a final concentration of 0.1  mM at the time of infection and 24 h after infection, to compensate for the low levels of endogenous heme in the insect cells. Cells were harvested, washed with PBS, and microsomes prepared according to standard procedures ([@bib17]) 48 h post infection. Briefly, cells were homogenised for 30s in 0.1 M Na/K-phosphate buffer (pH 7.4), containing 1 mM EDTA and DTT, and 200 mM sucrose, using a tissue grinder, and the homogenate centrifuged for 10 min at 680 g at 4 °C. The supernatant recovered was centrifuged for 20 min at 10,000 g and the decanted supernatant centrifuged for a further 1 h at 100,000 g at 4 °C. The pellet obtained was resuspended in 0.1 M Na/K-phosphate buffer (pH 7.6) containing 1 mM EDTA and DTT, and 10% v/v glycerol, using a Dounce tissue grinder. Cytochrome P450 expression and functionality was estimated by measuring the CO-difference spectra in reduced samples on a SLM AMINCO Dual Wavelength Spectrophotometer DW 2000 (SLM instruments) and scanning from 500 nm to 400 nm ([@bib17]). The protein content of samples was determined using Bradford reagent (Sigma-Aldrich, USA) and bovine serum albumin (BSA) as a reference.

2.6. Insecticide metabolism and model substrate profiling {#sec2.6}
---------------------------------------------------------

Metabolism of thiacloprid and acetamiprid were assessed by incubating recombinant P450/CPR (50μg/well) or control virus/CPR (50μg/well) with a range of substrate concentrations (200-3.1  μM) in the presence of an NADPH regeneration system (Promega, USA) at 30 ± 1 °C, shaking, for 1 h. Three replicates were performed for each data point and the total assay volume was 200 μl. The breakdown rate was assayed exactly as described above with a single concentration of substrate (200 μM). Samples incubated without NADPH served as an additional control. The reactions were terminated by the addition of 800 μl of ice-cold acetonitrile, centrifuged for 10 min at 3000 g and the supernatant subsequently analysed by tandem mass spectrometry as described previously ([@bib22]). For chromatography on a Waters Acquity HSS T3 column (2.1 × 50mm, 1.8  μm), acetonitrile/water/0.1% formic acid was used as the eluent in gradient mode. For detection and quantification in positive ion mode, the MRM transitions 253 \> 186, 269 \> 202 (thiacloprid, OH-thiacloprid), and 223 \> 126, 209 \> 126 (acetamiprid and *N*-desmethyl acetamiprid) were monitored. The peak integrals were calibrated externally against a standard calibration curve. The linear range for the quantification of neonicotinoids and their hydroxylated (thiacloprid) and *N*-desmethylated (acetamiprid) metabolites was 0.1--1000  ng ml^−1^. Recovery rates of parent compounds using microsomal fractions without NADPH were normally close to 100%. All statistical calculations and substrate turnover from two independent reactions were plotted vs. Controls and Michaelis-Menten kinetics determined using GraphPad Prism version 7 (GraphPad Software, USA).

2.7. Generation of transgenic *D. melanogaster* {#sec2.7}
-----------------------------------------------

All Drosophila strains were maintained on standard fly food (Bloomington formulation) at 25 °C, on a 12/12 h light/dark cycle and 65% relative humidity. *Cyp9Q6* was amplified from *B. terrestris* genomic DNA and cloned into the attB-carrying plasmid pUAST (pUASTattB_EF362409) using the *Eco*RI and *Xba*I restriction sites. Injection mixes containing 0.5x phosphate buffer pH 6.8 (0.05 mM sodium phosphate, 2.5 mM KCl), 300 ng/μl of the *pUAST-Cyp9Q6* construct and 200  mg l^−1^ fluorescein sodium salt were delivered into pre-blastoderm embryos of an integration strain (y w M(eGFP, vas-int, dmRFP)ZH-2A; P{CaryP}. attp40) sourced from the Fly Facility, University of Cambridge, using an inverted microscope (eclipse TieU Nikon, Japan) equipped with a 10x/0.25 lens, 10x/22 eyepiece and fluorescence illumination and a FemtoJet express micro-injector (Eppendorf, Hamburg, Germany) controlled by a motorised TransferMan NK2 micromanipulator (Eppendorf, Hamburg, Germany). Injection needles were prepared according to [@bib12]. Survivors were back-crossed and F1 individuals were screened for the presence of the *white* gene, which generates flies with orange eyes. Homozygous stocks for the integration of *pUAST-Cyp9Q6* at *attP40* were generated by inter-crossing orange eyed flies and selecting for red eyed individuals. Control flies carrying an empty pUAST plasmid were generated following the same procedures described above.

2.8. Transgenic *D. melanogaster* bioassays {#sec2.8}
-------------------------------------------

The UAS/GAL4 system was used to drive the expression of *Cyp9Q6*. Male flies, homozygous for *pUAST-Cyp9Q6* (*UAS::CYP9Q6*) or an empty *pUAST* plasmid inserted at the same genomic location (*UAS*:*empty*), were crossed to virgin females of a heat-shock inducible GAL4 driver strain (w\[\*\];P{wmC\] = GAL4-Hsp70.PB}89-2-1) to generate *UAS::CYP9Q6/* + *;Hsp::GAL4/* + and *UAS::empty/* + *;Hsp::GAL4/* + strains, respectively. Overexpression of *Cyp9Q6* in *UAS::CYP9Q6/* + *;Hsp::GAL4/* + flies was confirmed via qPCR with the *UAS::CYP9Q6* parental strain used as a control for the relative comparisons. Reactions were setup as presented in section [2.4](#sec2.4){ref-type="sec"}, a single biological replicate consisted of 5 heat-shock treated adult females. Over 600 four to eight-day old female flies from each genotype (*UAS::CYP9Q6/* + *;Hsp::GAL4/* + and *UAS::empty/* + *;Hsp::GAL4/* + ) were selected and used in contact/feeding bioassays. 24 h prior to bioassays, flies were heat-shock treated three times for 30 min at 37 °C, with 1-h intervals, to induce the expression of *Cyp9Q6*. Groups of 20 flies were transferred to vials, previously coated with 100 μl of an insecticide dilution, containing 3 ml of a settled agar-sucrose solution. Each bioassay used five different insecticide concentrations, five replications per concentration and the number of dead flies was recorded after 48 h. Control mortality was assessed using vials containing agar-sucrose without insecticide. Lethal concentrations (LC~50~ values) and 95% confidence limits were calculated by probit analysis using Genstat version 16 (VSN International, UK). Statistical significance was calculated using two tailed *t*-test in GraphPadprism version 7 (GraphPad Software, USA).

3. Results and discussion {#sec3}
=========================

Phylogeny ([Supplementary figure 1](#appsec1){ref-type="sec"}) of the CYP9 P450 gene family in the annotated genomes of Apis and Bombus revealed that *A. mellifera* had three complete CYP9Q genes while *B. terrestris* had only two (the previously characterised CYP9Q4 and CYP9Q5). To investigate if an additional CYP9Q gene was present in *B. terrestris* we performed an *in silico* re-analysis of P450 sequences in the *B. terrestris* genome.

3.1. Identification of CYP9Q6 in the genome of *B. terrestris* {#sec3.1}
--------------------------------------------------------------

Two partial protein sequences (NCBI accession\'s [XP_020718536.1](ncbi-p:XP_020718536.1){#intref0015} and [XP_003403396.2](ncbi-p:XP_003403396.2){#intref0020}) with high level homology to the CYP9Q sub-family were identified in the public protein database ([@bib16]) by BLASTp searches using *B. terrestris* CYP9Q4 and CYP9Q5 sequences as templates. Alignment of these partial transcripts to either CYP9Q4 or CYPQ5 indicated they may correspond to different regions of a novel, full-length P450 sequence ([Fig. 1](#fig1){ref-type="fig"}A). tBLASTn of the partial protein sequences against the *B. terrestris* genome identified two separate genomic locations, NCBI accession\'s [NC_015762.1](ncbi-n:NC_015762.1){#intref0025} and NW_003568850.1. Accession [NC_015762.1](ncbi-n:NC_015762.1){#intref0030} is a large scaffold previously identified as the location of *CYP9Q4* and *CYP9Q5*. The BLAST match was located approximately 3000bp downstream of the *CYP9Q4* gene locus, immediately upstream of a sequence gap in the assembly.Fig. 1**(**A**)** Alignment of the two partial transcripts data-mined from the NCBI publicly available *Bombus terrestris* genome database with CYP9Q5. The overlapping region of the two partial transcripts is highlighted. **(B)** Amino acid identity between CYP9Qs from *B. terrestris* (Bt) and *A. mellifera* (Am)*.*Fig. 1

Amplification of the predicted novel ORF by RT-PCR yielded a single 1.5 Kb cDNA, confirming that the two partial transcripts are in fact part of a single expressed mRNA. PCR on genomic DNA yielded the same result, suggesting that the novel gene is intronless (as is the case for CYP9Q4 and CYP9Q5, and CYP9Q1-3 of *A. mellifera*) and forms part of the same genomic locus. Sequencing of both the genomic and reversed transcribed mRNA (cDNA) amplicons further confirmed that this is a novel, full-length P450 ORF. No premature stop codons were found in either sequence suggesting that the gene is not a pseudogene and is likely to be functional. The protein sequence of the novel gene shares 62.6% and 61.5% identity with *CYP9Q4* and *CYP9Q5* respectively and 55.4% identity with *A. mellifera CYP9Q3* ([Fig. 1](#fig1){ref-type="fig"}B), known to be a primary metaboliser of *N*-cyanoamidine neonicotinoids in this species ([@bib10]).

Previous work on the CYP9Q P450s in *A. mellifera* and *B. terrestris* revealed high levels of expression of certain members of the family in tissues with a known role in xenobiotic detoxification or sites of insecticide action, such as the Malpighian tubules and the brain. Tissue expression profiling of *CYP9Q6* mRNA transcripts revealed a slightly higher expression profile in the bumblebee brain in comparison to the midgut or Malpighian tubules ([Fig. 3](#fig3){ref-type="fig"}), although the brain expression bias is much less pronounced in comparison to CYP9Q4 ([@bib10]). These results are consistent with the high expression of *A. mellifera* CYP9Q3 in the brain ([@bib10]), suggesting that *B. terrestris* CYP9Q6 may play a similar functional role in protecting this sensitive tissue from xenobiotics that cross the blood-brain barrier.Fig. 2(A and C) Kinetics of acetamiprid and thiacloprid for the CYP9Q sub-family. Data for CYP9Q4 and Q5 was collated from Manjon et al. ([@bib10]). N = 3, K~m~ values shown on graph ±standard deviation. V~max~ values for Q6 are 62.44 ± 1.21 (acetamiprid), 60.87 ± 4.72 (thiacloprid). (B and D**)** Breakdown of acetamiprid and thiacloprid by *B. terrestris* CYP9Q enzymes. CYP9Q4 and Q5 data taken from Manjon et al. ([@bib10]). Error bars represent standard deviation, N = 3. Significance is displayed above, NS- not significant, \*\*\*\* P \< 0.0001 (One-way ANOVA with Tukey test).Fig. 2Fig. 3Tissue-specific expression of CYP9Q6 transcripts in adult female worker. Significant differences in expression relative to the brain are indicated with \*. \*P = 0.0089, \*\*P = 0.0113 (two tailed T-test). N = 8 individual organs, error bars represent 95% confidence limits.Fig. 3

3.2. CYP9Q6 metabolises *N*-cyanoamidine neonicotinoids *in vitro* {#sec3.2}
------------------------------------------------------------------

To examine the capacity of CYP9Q6 to metabolise the *N*-cyanoamidine neonicotinoids thiacloprid and acetamiprid *in vitro,* CYP9Q6 was co-expressed with house fly cytochrome P450 reductase (CPR) in an insect cell line and microsomal preparations were incubated with each insecticide. Analysis of the resulting metabolites, by liquid chromatography tandem mass spectrometry (LC-MS/MS), revealed that recombinant CYP9Q6 readily metabolises both compounds in the presence of NADPH ([Fig. 2](#fig2){ref-type="fig"}). The K~m~ values for thiacloprid and acetamiprid were 15.83 and 27.32 μM respectively, with V~max~ values of 1.352 and 1.318 nmol product/nmol of active P450. Since the experimental setup for CYP9Q6 directly mirrored the previously reported methods for CYP9Q4 and CYPQ5, a direct comparison of the apparent rate of metabolism for CYP9Q6 and the other two CYP9Q P450s was possible. Data presented in [@bib10] was converted from mg/ml to active nmol P450 enzyme to normalise for any difference in the expression of active P450 (see [Supplementary figure 3](#appsec1){ref-type="sec"}). This showed that CYP9Q6 is 20 times more active at metabolising acetamiprid compared to either CYP9Q4 or CYP9Q5, while it is 3 (CYP9Q4) and 16 (CYP9Q5) times more active at metabolising thiacloprid. These results suggest that CYP9Q6 is the more efficient metaboliser for both compounds in *B. terrestris* ([Fig. 2](#fig2){ref-type="fig"}).

3.3. Model-substrate profile and catalytic site of CYP9Q6 {#sec3.3}
---------------------------------------------------------

A range of coumarin and resorufin model substrates were tested against CYP9Q6 expressed in microsomes. The enzyme does not exhibit a particularly strong affinity to any of these test compounds but did demonstrate a slight preference for simple O-alkyl coumarins and resorufins ([Supplementary figure 2](#appsec1){ref-type="sec"}). This contrasts with the other two previously described *B. terrestris* CYP9Q proteins, CYP9Q4 and CYP9Q5, which only show activity against coumarins with methoxy type moieties ([@bib10]). Thus, CYP9Q6 exhibits a greater promiscuity when presented with model substrates although with a low overall turnover. In contrast, *A*. *mellifera* CYP9Q3 efficiently metabolises a broad range of coumarins ([@bib10]).

Protein alignments of CYP9Q6 with other members of the CYP9Q sub-family revealed an amino acid substitution at a highly conserved A(A,G)X(E,D)T motif of the I-Helix, known as the oxygen binding motif, which is part of a substrate recognition site 4 ([Fig. 4](#fig4){ref-type="fig"}). In CYP9Q P450s with high affinity for *N*-cyanoamidine neonicotinoids, including bumblebee CYP9Q6 and honeybee CYP9Q3, a serine is found at the normally highly conserved threonine position within the motif. Likewise, CYP9Q4, which metabolises both thiacloprid and acetamiprid, also diverges from the conserved threonine and has an alanine substitution. In contrast, other members of the CYP9Q family in *A. mellifera* (CYP9Q1 and CYP9Q2) and *B. terrestris* (CYP9Q5) which metabolise neonicotinoids with much lower efficiency, if at all, have the conserved threonine ([@bib10]). Further evidence indicative of the potential importance of the amino acid at this position comes from work on a neonicotinoid resistant strain of brown planthopper *Nilaparvata lugens* ([@bib13]; [@bib23]). In this example the CYP6ER1 P450 variant responsible for resistance to imidacloprid has a threonine to serine substitution; replication of this serine substitution in the wild-type enzyme resulted in a marked increase in the efficiency of imidacloprid detoxification ([@bib23]). Finally, a threonine to proline substitution is found in an imidacloprid resistant strain of *Bemisia tabaci*, where overexpression of CYP6CM1 is linked with imidacloprid resistance ([@bib8]). Molecular docking and dynamic simulations of the interactions of imidacloprid with this enzyme revealed that Proline −326 forms part of the hydrophobic interface of the binding cavity and may stabilize binding of imidacloprid in the active site ([@bib9]).Fig. 4Protein alignment of the A(A,G)X(E,D)T motif of the I-Helix region of cytochrome P450s belonging to CYP9Q sub-family in *Apis mellifera* (Am) or *Bombus terrestris* (Bt) and 4 other P450s shown to metabolise neonicotinoid insecticides in insect pest species: *Bemisa tabaci* CYP6CM1, *Myzus persicae* CYP6CY3, *Drosophila melanogaster* CYP6G1 and *Nilaparvata lugens* CYP6ER1vA. The normally highly conserved threonine in the oxygen-binding motif is highlighted.Fig. 4

Although the modification of the threonine residue within the oxygen binding motif appears to be important in allowing P450 enzymes to break down neonicotinoid compounds, it does not appear to be essential since other P450\'s associated with neonicotinoid metabolism, namely *Myzus persicae* CYP6CY3 ([@bib1]) and *Drosophila melanogaster* CYP6G1 ([@bib7]), do not have equivalent substitutions at this position.

3.4. CYP9Q6 expression in transgenic *D. melanogaster* {#sec3.4}
------------------------------------------------------

To further confirm the role of CYP9Q6 in metabolising *N*-cyanoamidine neonicotinoids *in vivo*, we generated a transgenic line of *D. melanogaster* expressing *CYP9Q6* and examined its sensitivity to thiacloprid and acetamiprid. Expression of the transgene was confirmed via qPCR ([Supplementary figure 4](#appsec1){ref-type="sec"}). In bioassays, flies expressing the CYP9Q6 transgene were significantly more resistant to both insecticides when compared to control flies of the same genetic background without the transgene ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). Flies expressing CYP9Q6 were approximately four times more resistant to thiacloprid ([Table 1](#tbl1){ref-type="table"}) and around 2.3 times more resistant to acetamiprid ([Table 2](#tbl2){ref-type="table"}). These results corroborate the metabolism assays with recombinant CYP9Q6 performed *in vitro* and demonstrate that this P450 can confer tolerance to thiacloprid and acetamiprid *in vivo*.Table 1Log-dose probit-mortality data for thiacloprid against *Drosophila melanogaster* CYP9Q6 and control strains.Table 1StrainGenotypeLD50 (mg/L)95%CLLD95 (mg/L)95%CLResistance ratio (LD50)Resistance ratio (LD95)Control*UAS::empty/* + *;Hsp::GAL4/*+77.558.8--99.8818.2551.4--1402.6CYP9Q6*UAS::CYP9Q6/*+*;Hsp::GAL4/*+309258--37033262473--47683.994.06Table 2Log-dose probit-mortality data for acetamiprid against *Drosophila melanogaster* CYP9Q6 and control strains.Table 2StrainGenotypeLD50 (mg/L)95%CLLD95 (mg/L)95%CLResistance ratio (LD50)Resistance ratio (LD95)Control*UAS::empty/* + *;Hsp::GAL4/*+9.38.37--10.3223.7920.6--28.34CYP9Q6*UAS::CYP9Q6/* + *;Hsp::GAL4/*+21.1919.65--22.8859.2651.32--71.162.282.49

4. Conclusions {#sec4}
==============

In summary, these data identify a novel CYP9Q P450 in *B. terrestris* that metabolises *N*-cyanoamidine neonicotinoids with high efficiency. This information, in combination with data on the previously characterised CYP9Q4 and CYP9Q5, can be used to identify and consequently avoid harmful pesticide effects on *B. terrestris* that may arise from the inadvertent inhibition of these enzymes ([@bib11]). In addition, by adding to the number of known insect P450 enzymes that metabolise neonicotinoids, we highlight amino acids in the active site of P450s that may be important determinants of binding and metabolism of these compounds. This represents a useful starting point to further characterise the structure/function determinants of neonicotinoid metabolism using site-directed mutagenesis.
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